Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 7/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770048 | 0.93 | PIM1 (0.43) | PIM1ADORA2BKDM5AVNN1 | |
| SCHEMBL5772393 | 0.92 | HCRTR1 (0.38) | PIM1PDE10AHCRTR1HCRTR2KDM5A | |
| SCHEMBL5873053 | 0.92 | KDM5A (0.37) | PIM1PDE10AHCRTR1HCRTR2KDM5A | |
| SCHEMBL5873094 | 0.89 | ADORA2A (0.37) | ADORA2APIM1ADORA2BPDE10AHCRTR1 | |
| SCHEMBL5872880 | 0.89 | CYP2C9 (0.43) | ADORA2APIM1ADORA2BKDM5AHTT | |
| SCHEMBL5795447 | 0.88 | PIM1 (0.41) | PIM1HTT | |
| SCHEMBL5872872 | 0.88 | MKNK1 (0.45) | PIM1KDM5AKDM4ELMNAHTT | |
| SCHEMBL5873037 | 0.87 | CYP3A4 (0.38) | PIM1HCRTR1HCRTR2KDM5AHTT | |
| SCHEMBL5773190 | 0.87 | HTR2C (0.45) | PIM1KDM4EHTT | |
| SCHEMBL5769674 | 0.87 | PIM1 (0.40) | PIM1HCRTR1HCRTR2KDM5AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581797-A4 | METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS | AMBERGEN INC (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| EP-1581797-A2 | METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS | Ambergen, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2004063714-A2 | METHODS FOR THE DETECTION, ANALYSIS AND ISOLATION OF NASCENT PROTEINS | AMBERGEN, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ADORA2A 4569/4885PIM1 1909/4885ADORA2B 4130/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ADORA2A 4569/4885PIM1 1909/4885ADORA2B 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.